Sunil Dhawan, MD
Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
Member of the Healthcare Council
Council Member Biography
Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed care. Dr. Dhawan also runs the clinical trial division in his group practice, East Bay Dermatology Medical Group, where he has performed over 25 trials for all the major pharmaceutical companies. He has consulted for companies such as Allergan, Obagi, Connetics, Galderma, Astellas, Medicis, Amgen, and Stiefel. Dr. Dhawan is on the board of the local physician run IPA, as well as the utilization committee of the largest IPA in Silicon Valley. (This is me - Update Profile)
Employment History
- 1992 - present
- Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
- 1990 - present
- Dermatologist, East Bay Dermatology Medical Group Inc
GLG NewsSM Analyses by Sunil Dhawan, MD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 19, 2009
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Presta Trial shows good results for Enbrel
October 14, 2009
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com
This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy,...
-
Will the withdrawl of Efalizumab effect the biologic market?
April 15, 2009
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
Efalizumab withdrawn from US Market | www.medscape.com
This article is important in that the withdrawal of efalizumab by Genentech was appropriate in view of its serious side effect of progressive multifocal leukoencephalopathy (PML). This biologic agent was already declining in usage because of its other side effects, and the presence of other strongcompetitors...
-
Aurobindo terbinafine approval- what effect will this have?
January 21, 2009
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, STANFORD UNIVERSITY
Aurobindo Pharma gets approval for Terbinafine Tablets | myiris.com
This article is important in that it confirms another terbinafine competitor to the Novartis Lamisil brand is being released. The majority of terbinafine prescriptions in North America are generic. The market for this product will be good at least until more effective oral or topical agents are released....
Leading institutions connect with Sunil Dhawan, MD through GLG
GLG Study Groups with Sunil Dhawan, MD(?)
| Study Group Name | No. Members |
|---|---|
| Cosmetic Dermatologists (US) | 280 |
| Dermatologists (US) | 616 |
| Hair Restoration Dermatologists (US) | 285 |
| Juvederm Users: Cosmetic Dermatologists (US) | 133 |
GLG Live Meetings with Sunil Dhawan, MD(?)
Sunil Dhawan, MD has not participated in any GLG Live Meetings.